RecruitingPhase 2NCT07472075

Melatonin Versus Placebo for Bipolar Disorder

Melatonin Versus Placebo for Bipolar Disorder - a Double Blinded Randomised Controlled Trial

Sponsor

Lars Vedel Kessing

Enrollment

200 participants

Start Date

May 8, 2026

Study Type

INTERVENTIONAL

Conditions

Bipolar Affective Disorder

Summary

The objective with this study is to conduct a 6-month RCT comparing effects of add-on melatonin versus add-on placebo on mood stabilisation and other critical patient outcomes in patients with BD and to test whether principal effects are antimanic, antidepressant and/or prophylactic against relapse

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Melatonin and a drug called Placebo for people with bipolar affective disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.